Evidence map›Paper›PMID 34642607›Full record

ArticleNature reviews. Materials2021

Clinical translation of silica nanoparticles.

Taskeen Iqbal Janjua, Yuxue Cao, Chengzhong Yu, Amirali Popat

Abstract read
In one paragraph

Article in Nature reviews. Materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

123 citing papers in PubMed.

  1. Review
  2. Article
  3. Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Piperazine-Functionalized Nanoparticles Enable Oral Insulin Delivery in Obese Mice.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Taskeen Iqbal Janjua *School of Pharmacy, The University of Queensland, Brisbane, Queensland Australia.ORCID 0000-0003-0931-1326
Yuxue Cao *School of Pharmacy, The University of Queensland, Brisbane, Queensland Australia.ORCID 0000-0002-3260-5480
Chengzhong YuAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland Australia.ORCID 0000-0003-3707-0785
Amirali PopatSchool of Pharmacy, The University of Queensland, Brisbane, Queensland Australia.ORCID 0000-0001-5401-3446

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Silica nanoparticles have entered clinical trials for a variety of biomedical applications, including oral drug delivery, diagnostics, plasmonic resonance and photothermal ablation therapy. Preliminary results indicate the safety, efficacy and viability of silica nanoparticles under these clinical scenarios.

Indexed as

Drug deliveryNanoparticles

Identifiers

PMID34642607
PMCPMC8496429

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.